Keros Therapeutics (KROS)
Keros Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.1M
Short interest
settlement 2026-10-15
6.5
Days to cover
+0.9 days vs prior
52.7%
Short share of volume
2026-11-02
7
Fails to deliver
settlement 2026-10-09
Wed 4 Nov
Next earnings
estimated date
-$91K
Insider flow, 90 days
1 buys, 4 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in KROS is 1,136,901 shares, down 205,719 shares over the last month. Over the last 48 readings it ranged from 985,590 shares (31 July 2026) to 6,781,420 shares (14 November 2025). The latest reading sits at the bottom of that range. At the reported average volume of 175K shares a day that is 6.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/kros" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,136,901 | -1.1% | 174,612 | 6.51 |
| 2026-09-30 | 1,149,418 | -14.4% | 205,020 | 5.61 |
| 2026-09-15 | 1,342,620 | +15.2% | 147,052 | 9.13 |
| 2026-08-31 | 1,165,086 | +1.4% | 191,301 | 6.09 |
| 2026-08-14 | 1,148,951 | +16.6% | 242,951 | 4.73 |
| 2026-07-31 | 985,590 | -6.9% | 166,397 | 5.92 |
| 2026-07-15 | 1,058,882 | +3.2% | 259,282 | 4.08 |
| 2026-06-30 | 1,026,323 | -27.1% | 403,759 | 2.54 |
| 2026-06-15 | 1,407,890 | -6.7% | 213,268 | 6.60 |
| 2026-05-29 | 1,508,786 | -11.5% | 332,403 | 4.54 |
| 2026-05-15 | 1,704,362 | +20.4% | 366,493 | 4.65 |
| 2026-04-30 | 1,415,972 | +1.2% | 263,969 | 5.36 |
| 2026-04-15 | 1,399,759 | -6.4% | 403,815 | 3.47 |
| 2026-03-31 | 1,494,814 | -24.9% | 568,956 | 2.63 |
| 2026-03-13 | 1,989,399 | -2.1% | 565,163 | 3.52 |
| 2026-02-27 | 2,031,197 | -14.8% | 307,757 | 6.60 |
| 2026-02-13 | 2,383,895 | +4.7% | 270,381 | 8.82 |
| 2026-01-30 | 2,277,105 | -2.9% | 257,538 | 8.84 |
| 2026-01-15 | 2,345,217 | -5.6% | 446,480 | 5.25 |
| 2025-12-31 | 2,484,362 | -7.7% | 541,908 | 4.58 |
| 2025-12-15 | 2,692,419 | -16.6% | 885,542 | 3.04 |
| 2025-11-28 | 3,228,958 | -52.4% | 1,343,425 | 2.40 |
| 2025-11-14 | 6,781,420 | +15.7% | 1,258,629 | 5.39 |
| 2025-10-31 | 5,862,479 | +53.5% | 1,084,229 | 5.41 |
| 2025-10-15 | 3,817,848 | -1.3% | 1,001,572 | 3.81 |
| 2025-09-30 | 3,867,988 | -16.2% | 322,739 | 11.98 |
| 2025-09-15 | 4,617,384 | +2.6% | 321,633 | 14.36 |
| 2025-08-29 | 4,501,318 | -6.9% | 543,817 | 8.28 |
| 2025-08-15 | 4,834,554 | -0.1% | 433,368 | 11.16 |
| 2025-07-31 | 4,841,195 | -4.1% | 452,983 | 10.69 |
| 2025-07-15 | 5,049,215 | -2.2% | 437,402 | 11.54 |
| 2025-06-30 | 5,164,330 | +9.8% | 502,445 | 10.28 |
| 2025-06-13 | 4,702,282 | -11.4% | 757,084 | 6.21 |
| 2025-05-30 | 5,306,156 | -8.1% | 576,856 | 9.20 |
| 2025-05-15 | 5,772,258 | +9.6% | 828,239 | 6.97 |
| 2025-04-30 | 5,266,448 | +19.5% | 1,096,189 | 4.80 |
| 2025-04-15 | 4,407,820 | +8.7% | 1,850,318 | 2.38 |
| 2025-03-31 | 4,053,717 | +0.8% | 664,202 | 6.10 |
| 2025-03-14 | 4,019,396 | -3.9% | 806,671 | 4.98 |
| 2025-02-28 | 4,182,765 | +1.2% | 1,084,023 | 3.86 |
| 2025-02-14 | 4,132,154 | -3.0% | 1,050,769 | 3.93 |
| 2025-01-31 | 4,259,099 | +6.0% | 1,823,869 | 2.34 |
| 2025-01-15 | 4,017,848 | -6.9% | 2,432,437 | 1.65 |
| 2024-12-31 | 4,313,793 | +42.6% | 1,351,442 | 3.19 |
| 2024-12-13 | 3,025,140 | +37.7% | 2,354,386 | 1.28 |
| 2024-11-29 | 2,197,295 | -1.2% | 378,448 | 5.81 |
| 2024-11-15 | 2,224,037 | -7.8% | 458,829 | 4.85 |
| 2024-10-31 | 2,412,173 | -11.3% | 313,386 | 7.70 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of KROS volume is 52.7%, down 6.7 points over the last five sessions. Over the last 30 readings it ranged from 27.9% (27 October 2026) to 72.6% (8 October 2026). The latest reading is 2.8 points above the 30-session average of 49.8%, on 41K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 21K | 41K | 52.7% | 60 |
| 2026-10-30 | 19K | 34K | 54.8% | 0 |
| 2026-10-29 | 20K | 70K | 29.1% | 0 |
| 2026-10-28 | 13K | 42K | 31.4% | 0 |
| 2026-10-27 | 16K | 56K | 27.9% | 0 |
| 2026-10-26 | 21K | 36K | 59.4% | 0 |
| 2026-10-23 | 12K | 25K | 47.3% | 0 |
| 2026-10-22 | 20K | 29K | 68.0% | 0 |
| 2026-10-21 | 22K | 63K | 35.6% | 0 |
| 2026-10-20 | 18K | 54K | 32.4% | 0 |
| 2026-10-19 | 35K | 94K | 37.2% | 0 |
| 2026-10-16 | 26K | 42K | 61.1% | 0 |
| 2026-10-15 | 7K | 19K | 34.7% | 0 |
| 2026-10-14 | 16K | 34K | 46.6% | 0 |
| 2026-10-13 | 20K | 37K | 52.9% | 0 |
| 2026-10-12 | 25K | 54K | 46.3% | 0 |
| 2026-10-09 | 30K | 67K | 45.6% | 28 |
| 2026-10-08 | 45K | 62K | 72.6% | 1 |
| 2026-10-07 | 39K | 59K | 64.9% | 0 |
| 2026-10-06 | 27K | 84K | 32.1% | 0 |
| 2026-10-05 | 26K | 44K | 58.4% | 0 |
| 2026-10-02 | 44K | 66K | 66.4% | 0 |
| 2026-10-01 | 16K | 34K | 45.6% | 0 |
| 2026-09-30 | 15K | 22K | 65.7% | 0 |
| 2026-09-29 | 14K | 27K | 49.8% | 0 |
| 2026-09-28 | 23K | 51K | 44.4% | 0 |
| 2026-09-25 | 35K | 56K | 62.2% | 0 |
| 2026-09-24 | 44K | 74K | 59.4% | 0 |
| 2026-09-23 | 26K | 42K | 62.8% | 0 |
| 2026-09-22 | 29K | 60K | 48.4% | 10 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in KROS is 7 shares, down 26 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (30 March 2026) to 59,364 shares (25 February 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 7 | $11.64 | $81 |
| 2026-09-08 | 33 | $11.32 | $374 |
| 2026-08-27 | 64 | $11.12 | $712 |
| 2026-08-26 | 572 | $11.68 | $7K |
| 2026-08-24 | 414 | $11.03 | $5K |
| 2026-08-14 | 1,136 | $10.66 | $12K |
| 2026-08-10 | 950 | $11.15 | $11K |
| 2026-08-04 | 3,142 | $10.11 | $32K |
| 2026-07-16 | 56 | $11.03 | $618 |
| 2026-07-01 | 296 | $10.70 | $3K |
| 2026-06-30 | 611 | $10.93 | $7K |
| 2026-06-25 | 2 | $10.92 | $22 |
| 2026-06-22 | 68 | $10.65 | $724 |
| 2026-06-18 | 97 | $10.41 | $1K |
| 2026-06-17 | 576 | $10.03 | $6K |
| 2026-06-16 | 5 | $10.24 | $51 |
| 2026-05-28 | 149 | $11.31 | $2K |
| 2026-05-06 | 643 | $11.77 | $8K |
| 2026-05-04 | 240 | $11.49 | $3K |
| 2026-05-01 | 155 | $11.12 | $2K |
| 2026-04-09 | 3,988 | $12.55 | $50K |
| 2026-04-08 | 300 | $12.24 | $4K |
| 2026-04-06 | 3 | $12.00 | $36 |
| 2026-04-01 | 1 | $11.04 | $11 |
| 2026-03-30 | 1 | $10.61 | $11 |
| 2026-03-27 | 20 | $11.08 | $222 |
| 2026-03-19 | 4 | $10.95 | $44 |
| 2026-03-16 | 23 | $11.02 | $253 |
| 2026-02-25 | 59,364 | $15.52 | $921K |
| 2026-02-06 | 7 | $17.24 | $121 |
Insider trades
SEC Form 4, newest first. JSONOver the last 90 days KROS insiders reported 1 open-market buy ($10K) against 4 sells ($101K), so the dollar flow leans toward selling. Latest filing: Tanini Annita (Corp. Controller & VP, Finance) on 2026-08-18.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-18 | Tanini Annita | Corp. Controller & VP, Finance | Sell | 1K | $10.29 | $13K | 45K |
| 2026-08-18 | Lerner Lorena Raquel | Chief Scientific Officer | Sell | 4K | $10.29 | $37K | 28K |
| 2026-08-18 | Newton Charles W. | Director | Sell | 551 | $10.30 | $6K | 12K |
| 2026-08-18 | Cho Esther | Chief Legal Officer | Sell | 4K | $10.29 | $46K | 36K |
| 2026-08-17 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $10.27 | $10K | 20K |
| 2026-07-15 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $10.61 | $11K | 19K |
| 2026-07-01 | Prener Anne | Director | Grant | 14K | $0.00 | $0 | 14K |
| 2026-06-15 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $10.19 | $10K | 18K |
| 2026-06-11 | Newton Charles W. | Director | Sell | 550 | $10.04 | $6K | 13K |
| 2026-06-04 | Seth Alpna | Director | Sell | 3K | $10.72 | $28K | 10K |
| 2026-06-04 | Knowles Julius | Director | Sell | 3K | $10.73 | $28K | 11K |
| 2026-06-04 | Farzan Nima | Director | Sell | 3K | $10.73 | $28K | 10K |
| 2026-06-03 | Knowles Julius | Director | Grant | 7K | $0.00 | $0 | 14K |
| 2026-06-03 | Seth Alpna | Director | Grant | 7K | $0.00 | $0 | 12K |
| 2026-06-03 | GRAY MARY ANN | Director | Grant | 7K | $0.00 | $0 | 12K |
| 2026-06-03 | Farzan Nima | Director | Grant | 7K | $0.00 | $0 | 12K |
| 2026-06-03 | BIENAIME JEAN JACQUES | Director | Grant | 7K | $0.00 | $0 | 17K |
| 2026-05-15 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $10.58 | $11K | 9K |
| 2026-04-15 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $11.70 | $12K | 8K |
| 2026-04-02 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 55K | $0.30 | $17K | 441K |
| 2026-03-09 | Newton Charles W. | Director | Grant | 13K | $0.00 | $0 | 13K |
| 2026-03-09 | BIENAIME JEAN JACQUES | Director | Buy | 2K | $11.21 | $22K | 7K |
| 2026-02-19 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Sell | 7K | $16.17 | $113K | 386K |
| 2026-02-18 | Lerner Lorena Raquel | Chief Science Officer | Sell | 4K | $16.35 | $63K | 31K |
| 2026-02-18 | Regnante Keith | CHIEF FINANCIAL OFFICER | Sell | 5K | $16.35 | $77K | 39K |
| 2026-02-18 | Cho Esther | SVP, General Counsel | Sell | 5K | $16.35 | $78K | 40K |
| 2025-11-21 | OrbiMed Genesis GP LLC | Director | Returned to company | 74K | $17.75 | $1.3M | 45K |
| 2025-11-21 | OrbiMed Genesis GP LLC | Director | Returned to company | 140K | $17.75 | $2.5M | 759K |
| 2025-11-21 | Knowles Julius | Director | Returned to company | 130K | $17.75 | $2.3M | 102K |
| 2025-11-21 | Knowles Julius | Director | Returned to company | 192K | $17.75 | $3.4M | 150K |
| 2025-11-21 | ORBIMED ADVISORS LLC | Director | Returned to company | 74K | $17.75 | $1.3M | 45K |
| 2025-11-21 | ORBIMED ADVISORS LLC | Director | Returned to company | 140K | $17.75 | $2.5M | 759K |
| 2025-11-21 | GORDON CARL L | Director | Returned to company | 74K | $17.75 | $1.3M | 45K |
| 2025-11-21 | GORDON CARL L | Director | Returned to company | 140K | $17.75 | $2.5M | 759K |
| 2025-10-15 | Schneeberger Daniel | TenPercentOwner | Sell | 743K | $17.75 | $13.2M | 0 |
| 2025-10-15 | Schneeberger Daniel | TenPercentOwner | Sell | 4.4M | $17.75 | $77.9M | 0 |
| 2025-10-15 | Schneeberger Daniel | TenPercentOwner | Sell | 255K | $17.75 | $4.5M | 0 |
| 2025-10-15 | Pontifax (China) IV L.P. | TenPercentOwner | Sell | 1.1M | $17.75 | $19.9M | 0 |
| 2025-10-15 | Pontifax (China) IV L.P. | TenPercentOwner | Sell | 1.2M | $17.75 | $21.8M | 0 |
| 2025-10-15 | Pontifax (China) IV L.P. | TenPercentOwner | Sell | 155K | $17.75 | $2.8M | 0 |
| 2025-10-15 | Pontifax (China) IV L.P. | TenPercentOwner | Sell | 2.3M | $17.75 | $40.6M | 0 |
| 2025-10-15 | ADAR1 Capital Management, LLC | 10% owner | Sell | 743K | $17.75 | $13.2M | 0 |
| 2025-10-15 | ADAR1 Capital Management, LLC | 10% owner | Sell | 255K | $17.75 | $4.5M | 0 |
| 2025-10-15 | ADAR1 Capital Management, LLC | 10% owner | Sell | 4.4M | $17.75 | $77.9M | 0 |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% owner | Sell | 155K | $17.75 | $2.8M | 0 |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% owner | Sell | 1.2M | $17.75 | $21.8M | 0 |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% owner | Sell | 1.1M | $17.75 | $19.9M | 0 |
| 2025-10-15 | Pontifax Management 4 G.P. (2015) Ltd. | 10% owner | Sell | 2.3M | $17.75 | $40.6M | 0 |
| 2025-09-03 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Grant | 91K | $0.00 | $0 | 393K |
| 2025-06-20 | Schneeberger Daniel | TenPercentOwner | Exercise (in or at the money) | 200 | $70.00 | $14K | 743K |
| 2025-06-20 | Schneeberger Daniel | TenPercentOwner | Exercise (in or at the money) | 100 | $60.00 | $6K | 4.4M |
| 2025-06-20 | Schneeberger Daniel | TenPercentOwner | Exercise (in or at the money) | 1K | $70.00 | $98K | 4.4M |
| 2025-06-20 | ADAR1 Capital Management, LLC | 10% owner | Exercise (in or at the money) | 200 | $70.00 | $14K | 743K |
| 2025-06-20 | ADAR1 Capital Management, LLC | 10% owner | Exercise (in or at the money) | 1K | $70.00 | $98K | 4.4M |
| 2025-06-20 | ADAR1 Capital Management, LLC | 10% owner | Exercise (in or at the money) | 100 | $60.00 | $6K | 4.4M |
| 2025-06-04 | BIENAIME JEAN JACQUES | Director | Grant | 5K | $0.00 | $0 | 5K |
| 2025-06-04 | Farzan Nima | Director | Grant | 5K | $0.00 | $0 | 5K |
| 2025-06-04 | GRAY MARY ANN | Director | Grant | 5K | $0.00 | $0 | 5K |
| 2025-06-04 | Seth Alpna | Director | Grant | 5K | $0.00 | $0 | 5K |
| 2025-06-04 | Nussbaum Ran | Director,TenPercentOwner | Grant | 5K | $0.00 | $0 | 5K |
| 2025-06-04 | Kariv Tomer | Director,TenPercentOwner | Grant | 5K | $0.00 | $0 | 5K |
| 2025-06-04 | GORDON CARL L | Director | Grant | 5K | $0.00 | $0 | 5K |
| 2025-06-04 | Knowles Julius | Director | Grant | 5K | $0.00 | $0 | 6K |
| 2025-04-09 | ADAR1 Partners, LP | TenPercentOwner | Buy | 74K | $10.33 | $768K | 4.4M |
| 2025-04-09 | ADAR1 Partners, LP | TenPercentOwner | Buy | 19K | $9.40 | $174K | 3.5M |
| 2025-04-09 | ADAR1 Partners, LP | TenPercentOwner | Buy | 16K | $9.40 | $154K | 744K |
| 2025-04-09 | ADAR1 Partners, LP | TenPercentOwner | Buy | 325K | $9.86 | $3.2M | 3.8M |
| 2025-04-09 | ADAR1 Partners, LP | TenPercentOwner | Buy | 500K | $10.33 | $5.2M | 4.3M |
| 2025-04-04 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Exercise or conversion | 49K | $0.30 | $15K | 302K |
| 2025-02-18 | Rovaldi Christopher | Chief Operating Officer | Grant | 60K | $0.00 | $0 | 60K |
| 2025-02-18 | Regnante Keith | CHIEF FINANCIAL OFFICER | Grant | 44K | $0.00 | $0 | 44K |
| 2025-02-18 | CHYUNG YUNG H. | Chief Medical Officer | Grant | 44K | $0.00 | $0 | 44K |
| 2024-08-13 | OrbiMed Genesis GP LLC | Director | Sell | 221K | $44.01 | $9.7M | 899K |
| 2024-08-13 | OrbiMed Genesis GP LLC | Director | Sell | 29K | $44.01 | $1.3M | 120K |
| 2024-08-13 | GORDON CARL L | Director | Sell | 29K | $44.01 | $1.3M | 120K |
| 2024-08-13 | GORDON CARL L | Director | Sell | 221K | $44.01 | $9.7M | 899K |
| 2024-01-04 | Regnante Keith | CHIEF FINANCIAL OFFICER | Exercise or conversion | 40K | $16.00 | $640K | 40K |
| 2024-01-04 | Regnante Keith | CHIEF FINANCIAL OFFICER | Sell | 40K | $45.29 | $1.8M | 0 |
| 2023-11-04 | Regnante Keith | Chief Financial Officer | Sell | 40K | $45.29 | $1.8M | 0 |
| 2023-11-04 | Regnante Keith | Chief Financial Officer | Exercise or conversion | 40K | $16.00 | $640K | 40K |
| 2023-06-09 | Regnante Keith | Chief Financial Officer | Sell | 16K | $45.03 | $720K | 4K |
| 2023-06-09 | Regnante Keith | Chief Financial Officer | Sell | 1K | $46.46 | $66K | 3K |
| 2023-06-09 | Regnante Keith | Chief Financial Officer | Sell | 3K | $47.25 | $122K | 0 |
| 2023-06-09 | Regnante Keith | Chief Financial Officer | Exercise or conversion | 20K | $16.00 | $320K | 20K |
| 2023-06-08 | Regnante Keith | Chief Financial Officer | Exercise or conversion | 20K | $16.00 | $320K | 20K |
| 2023-06-08 | Regnante Keith | Chief Financial Officer | Sell | 17K | $47.66 | $825K | 3K |
| 2023-06-08 | Regnante Keith | Chief Financial Officer | Sell | 3K | $48.65 | $131K | 0 |
| 2023-04-08 | Seehra Jasbir | Chief Executive Officer | Exercise or conversion | 4K | $0.48 | $2K | 253K |
| 2022-11-29 | Kariv Tomer | Director,TenPercentOwner | Exercise (in or at the money) | 2K | $0.00 | $0 | 1.1M |
| 2022-11-29 | Kariv Tomer | Director,TenPercentOwner | Exercise (in or at the money) | 4K | $0.00 | $0 | 2.3M |
| 2022-11-29 | Kariv Tomer | Director,TenPercentOwner | Exercise (in or at the money) | 2K | $0.00 | $0 | 1.2M |
| 2022-11-29 | Nussbaum Ran | Director,TenPercentOwner | Exercise (in or at the money) | 2K | $0.00 | $0 | 1.1M |
| 2022-11-29 | Nussbaum Ran | Director,TenPercentOwner | Exercise (in or at the money) | 2K | $0.00 | $0 | 1.2M |
| 2022-11-29 | Nussbaum Ran | Director,TenPercentOwner | Exercise (in or at the money) | 4K | $0.00 | $0 | 2.3M |
| 2022-11-29 | Pontifax Late Stage GP Ltd. | TenPercentOwner | Exercise (in or at the money) | 2K | $0.00 | $0 | 1.1M |
| 2022-11-29 | Pontifax Late Stage GP Ltd. | TenPercentOwner | Exercise (in or at the money) | 4K | $0.00 | $0 | 2.3M |
| 2022-11-29 | Pontifax Late Stage GP Ltd. | TenPercentOwner | Exercise (in or at the money) | 2K | $0.00 | $0 | 1.2M |
| 2022-07-15 | Lachey Jennifer | Chief Scientific Officer | Sell | 46K | $30.00 | $1.4M | 95K |
| 2022-07-15 | Lachey Jennifer | Chief Scientific Officer | Exercise or conversion | 46K | $0.30 | $14K | 141K |
| 2022-07-13 | Lachey Jennifer | Chief Scientific Officer | Sell | 2K | $30.00 | $57K | 95K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for KROS worth $593K at the prices reported; 1 in the last 90 days worth $6K. Latest: Newton Charles W. filed on 2026-08-18 to sell 551 shares ($6K) from 2026-08-18.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-18 | Newton Charles W.Director | 551 | $6K | 0.003% | 2026-08-18 | UBS Financial Services, Inc. |
| 2026-06-11 | Newton Charles W.Director | 550 | $5K | 0.003% | 2026-06-11 | UBS Financial Services, Inc. |
| 2026-06-04 | Knowles JuliusDirector | 3K | $28K | 0.013% | 2026-06-04 | UBS Financial Services, Inc. |
| 2026-06-04 | Seth AlpnaDirector | 3K | $28K | 0.013% | 2026-06-04 | UBS Financial Services, Inc. |
| 2026-06-04 | Farzan NimaDirector | 3K | $28K | 0.013% | 2026-06-04 | UBS Financial Services, Inc. |
| 2026-03-31 | OrbiMed Genesis Master Fund, LPShareholder, Director | 45K | $497K | 0.229% | 2026-03-31 | Themis Trading LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of KROS in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock Portfolio Management LLC at 9.1% of the class (1,813,870 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 1 | BlackRock Portfolio Management LLCparent holding company | 1.8M | 9.1% | 2026-09-30 |
| 2026-07-29 | 13G/Ano. 5 | BlackRock, Inc.parent holding company | 1.7M | 8.4% | 2026-06-30 |
| 2026-05-15 | 13G | Daniel Mackparent holding company | 1.4M | 6.9% | 2026-03-31 |
| 2026-05-15 | 13G | Wilmot B. Harkeyparent holding company | 1.4M | 6.9% | 2026-03-31 |
| 2026-05-15 | 13G | Nantahala Capital Management, LLCinvestment adviser | 1.4M | 6.9% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 1 | TANG CAPITAL PARTNERS, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | TANG CAPITAL PARTNERS III, INCcorporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | TANG CAPITAL PARTNERS IV, INCcorporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | TANG CAPITAL MANAGEMENT, LLCother entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | KEVIN TANGindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | D. E. Shaw & Co., L.P.investment adviser, partnership | 756K | 3.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | D. E. Shaw & Co., L.L.C.other entity | 755K | 3.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | David E. Shawindividual | 756K | 3.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | EMAI Management, LLCother entity | 824K | 2.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Madison Avenue International LPpartnership | 824K | 2.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Madison Avenue Partners, LPpartnership | 824K | 2.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Madison Avenue GP, LLCother entity | 824K | 2.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Caraway Jackson Investments LLCother entity | 824K | 2.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Eli Samahaindividual | 824K | 2.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Michael Gelbandindividual, parent holding company | 13K | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | ExodusPoint Capital Management, LPinvestment adviser, partnership | 13K | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | ExodusPoint Capital Partners GP, LLCcorporation, parent holding company | 13K | 0.0% | 2025-12-31 |
| 2025-10-16 | 13D/Ano. 2 | Pontifax Management 4 GP (2015) Ltd.corporation | 0 | 0.0% | 2025-10-15 |
| 2025-10-16 | 13D/Ano. 2 | Pontifax (Israel) IV, L.P.partnership | 0 | 0.0% | 2025-10-15 |
| 2025-10-16 | 13D/Ano. 2 | Pontifax (Cayman) IV, L.P.partnership | 0 | 0.0% | 2025-10-15 |
| 2025-10-16 | 13D/Ano. 2 | Pontifax (China) IV, L.P.partnership | 0 | 0.0% | 2025-10-15 |
| 2025-10-16 | 13D/Ano. 2 | Pontifax Late Stage Fund L.P.partnership | 0 | 0.0% | 2025-10-15 |
| 2025-10-16 | 13D/Ano. 2 | Pontifax Late Stage GP Ltd.corporation | 0 | 0.0% | 2025-10-15 |
| 2025-10-15 | 13D/Ano. 5 | ADAR1 Capital Management, LLCother entity | 0 | 0.0% | 2025-10-15 |
| 2025-10-15 | 13D/Ano. 5 | ADAR1 Capital Management GP, LLCother entity | 0 | 0.0% | 2025-10-15 |
| 2025-10-15 | 13D/Ano. 5 | Daniel Schneebergerindividual | 0 | 0.0% | 2025-10-15 |
13F holders
Tracked managers holding KROS at their latest 13F. JSON7 of the 30 tracked managers held KROS at their latest 13F, $26.0M in total at quarter-end prices. AQR Capital Management is the largest at $10.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 968K | $10.4M | 0.00% | +561K |
| Citadel Advisors | 2026-06-30 | 396K | $4.2M | 0.00% | -11K |
| Renaissance Technologies | 2026-06-30 | 359K | $3.8M | 0.01% | -94K |
| D. E. Shaw & Co. | 2026-06-30 | 267K | $2.9M | 0.00% | -242K |
| Two Sigma Investments | 2026-06-30 | 247K | $2.6M | 0.00% | -117K |
| Millennium Management | 2026-06-30 | 185K | $2.0M | 0.00% | +78K |
| Point72 Asset Management | 2026-06-30 | 10K | $111K | 0.00% | -99K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Keros Therapeutics reported revenue of $0, down 100.0% from the same quarter a year earlier, and net loss of $28.7M (-1.45 diluted EPS). In FY 2025 it generated $107.5M of operating cash flow and spent $375.0M on buybacks.
- Cash
- $257.6M
- Equity
- $262.3M
- Total assets
- $287.6M
- Shares outstanding
- 19,827,188
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $0 | -$28.7M | n/a | -1.45 |
| Q1 FY 2026 | 2026-03-31 | $367K | -$23.7M | -6459.9% | -1.21 |
| Q4 FY 2025derived | 2025-12-31 | $385K | -$23.5M | -6093.8% | n/a |
| Q3 FY 2025 | 2025-09-30 | $14.3M | -$7.3M | -51.0% | -0.18 |
| Q2 FY 2025 | 2025-06-30 | $18.2M | -$30.7M | -169.0% | -0.76 |
| Q1 FY 2025 | 2025-03-31 | $211.2M | $148.5M | 70.3% | 3.62 |
| Q4 FY 2024derived | 2024-12-31 | $3.0M | -$46.0M | -1513.0% | n/a |
| Q3 FY 2024 | 2024-09-30 | $388K | -$53.0M | -13648.5% | -1.41 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $244.1M | $87.0M | $107.5M | $1.6M | $375.0M | n/a |
| FY 2024 | 2024-12-31 | $3.5M | -$187.4M | -$160.9M | $1.9M | $0 | n/a |
| FY 2023 | 2023-12-31 | $151K | -$153.0M | -$124.5M | $2.5M | n/a | n/a |
| FY 2022 | 2022-12-31 | $0 | -$104.7M | -$70.1M | $1.2M | n/a | n/a |
| FY 2021 | 2021-12-31 | $20.1M | -$58.7M | -$62.1M | $1.0M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
Keros Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Keros Therapeutics (KROS), SEC CIK 1664710, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-18.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-03.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-18.JSON and CSV
- Company record
- EDGAR filing index for CIK 1664710Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of KROS is sold short?
1,136,901 shares were held short at the 2026-10-15 settlement, 6.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is KROS's daily short volume?
On 2026-11-02, 21,469 of the 40,754 KROS shares reported to FINRA were sold short, 52.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does KROS have fails to deliver?
The SEC's latest file shows 7 KROS shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are KROS insiders buying or selling?
Over the last 90 days KROS insiders reported 1 open-market buy ($10K) against 4 sells ($101K), so the dollar flow leans toward selling. Latest filing: Tanini Annita (Corp. Controller & VP, Finance) on 2026-08-18.
Have KROS insiders filed to sell?
6 Form 144 notices on file for KROS worth $593K at the prices reported; 1 in the last 90 days worth $6K. Latest: Newton Charles W. filed on 2026-08-18 to sell 551 shares ($6K) from 2026-08-18.
Who owns 5% or more of KROS?
5 holders report 5% or more of KROS in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock Portfolio Management LLC at 9.1% of the class (1,813,870 shares), filed 2026-10-27 for an event on 2026-09-30.
What did KROS report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Keros Therapeutics reported revenue of $0, down 100.0% from the same quarter a year earlier, and net loss of $28.7M (-1.45 diluted EPS). In FY 2025 it generated $107.5M of operating cash flow and spent $375.0M on buybacks.
Which tracked 13F managers own KROS?
7 of the 30 tracked 13F managers held KROS shares at their latest filing, $26.0M in all. The largest: Cliff Asness's AQR Capital Management (968K shares, $10.4M), Ken Griffin's Citadel Advisors (396K shares, $4.2M), Renaissance Technologies (359K shares, $3.8M), D. E. Shaw & Co. (267K shares, $2.9M), Two Sigma Investments (247K shares, $2.6M), Izzy Englander's Millennium Management (185K shares, $2.0M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.